Malignant tumor
Conditions
Interventions
The group of patient-reported outcomes (PRO group):Patient-reported outcomes (PRO), and relevant symptomatic interventions were carried out based on the early warning values of the questionnaire
Sponsors
Ordos Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged >= 18 years old, who have been pathologically diagnosed with gastrointestinal malignant tumors, have household registration in pastoral and agricultural areas (rural areas at the county level and below, pastoral areas), and currently live in pastoral and agricultural areas for a long time; 2. Patients who are planned to receive chemotherapy regimens based on oxaliplatin, irinotecan or fluorouracil, including SOX, XELOX, FOLFOX, FOLFIRI, XELRI regimens. Combination of the above regimens with PD-1, bevacizumab or cetuximab is allowed; 3. Karnofsky Performance Status (KPS) score >= 70 points; 4. No obvious abnormalities in liver and kidney functions, routine blood tests, and electrocardiogram before chemotherapy. Blood tests must meet the following criteria: platelet count > 85×10?/L, white blood cell count > 3.5×10?/L, neutrophil count > 1.5×10?/L, serum alanine aminotransferase and aspartate aminotransferase = 12 months and plan to receive >= 4 cycles of chemotherapy; 6. Provide informed consent and be able to complete WeChat follow-up; 7. The patient himself/herself or a direct relative has a mobile phone device that can answer calls or receive text messages, and is able to complete filling out the EORTC QLQ-C30 quality of life scale independently or with the assistance of a family member.
Exclusion criteria
Exclusion criteria: 1. Patients who cannot understand the research content. 2. Tumor patients who change the treatment method or chemotherapy regimen. 3. Patients with severe mental illness or cognitive impairment who cannot cooperate with the research. 4. Patients who voluntarily terminate anti-tumor chemotherapy or interrupt chemotherapy due to other serious diseases during chemotherapy. 5. Patients with low participation and cooperation who cannot complete regular follow-up. 6. Patients who participate in other interventional clinical studies simultaneously.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Health-related quality of life (HRQOL); | — |
Secondary
| Measure | Time frame |
|---|---|
| The duration of adverse reactions after chemotherapy.; | — |
Countries
China
Contacts
Public ContactLi Quanfu
Ordos Central Hospital
Outcome results
None listed